AstraZeneca Pharma Intrinsic Value
AstraZeneca Pharma intrinsic value. AstraZeneca Pharma (ASTRAZEN) median intrinsic value is ₹2445.20 from 10 valuation models (range ₹1834–₹10556), vs current price ₹6113.00 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse AstraZeneca Pharma ownership pattern to track promoter, FII and institutional holdings.
ASTRAZEN Valuation Methods Summary — DCF, Graham Number & P/E
AstraZeneca Pharma intrinsic value across 10 models vs current price ₹6113.00 — upside/downside and value range per method. For current market price and key ratios, visit AstraZeneca Pharma share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1833.90 | ₹1467.12 - ₹2200.68 | -70.0% | EPS: ₹71.10, Sector P/E: 22x |
| Book Value Method | asset | ₹3492.00 | ₹3142.80 - ₹3841.20 | -42.9% | Book Value/Share: ₹1746.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹10556.00 | ₹9500.40 - ₹11611.60 | +72.7% | Revenue/Share: ₹5278.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5420.00 | ₹4878.00 - ₹5962.00 | -11.3% | EBITDA: ₹271.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2445.20 | ₹1956.16 - ₹2934.24 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1833.90 | ₹1650.51 - ₹2017.29 | -70.0% | EPS Growth: 15.7%, Fair P/E: 12.5x |
| Growth Adjusted P/E | growth | ₹1833.90 | ₹1650.51 - ₹2017.29 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹5696.00 | ₹5126.40 - ₹6265.60 | -6.8% | ROE: 20.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1833.90 | ₹1650.51 - ₹2017.29 | -70.0% | EPS: ₹71.10, BVPS: ₹1746.00 |
| Dividend Yield Method | dividend | ₹1833.90 | ₹1650.51 - ₹2017.29 | -70.0% | DPS: ₹36.00, Target Yield: 2.5% |
ASTRAZEN Intrinsic Value vs Market Price — All Valuation Models
AstraZeneca Pharma fair value range ₹1834–₹10556 vs current market price ₹6113.00 across 10 valuation models. Browse ASTRAZEN annual financials for revenue, profit, balance sheet and cash flow data.
ASTRAZEN Intrinsic Value Analysis — Undervalued or Overvalued?
AstraZeneca Pharma median intrinsic value ₹2445.20, current price ₹6113.00 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of ASTRAZEN?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of AstraZeneca Pharma (ASTRAZEN) is ₹2445.20 (median value). With the current market price of ₹6113.00, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹1833.90 to ₹10556.00, indicating ₹1833.90 - ₹10556.00.
Is ASTRAZEN undervalued or overvalued?
Based on our multi-method analysis, AstraZeneca Pharma (ASTRAZEN) appears to be trading above calculated value by approximately 60.0%.
ASTRAZEN Financial Health — Key Ratios vs Industry Benchmarks
AstraZeneca Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 20.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ASTRAZEN Cash Flow Quality — Operating & Free Cash Flow
AstraZeneca Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-15 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹65 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹28 Cr | ₹28 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹58 Cr | ₹58 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹101 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |